What Is the Same
The active ingredient — semaglutide — is identical. It is the same GLP-1 receptor agonist that activates the same receptors, produces the same physiological effects, and follows the same titration logic. A compounded semaglutide injection of 0.5 mg binds to GLP-1 receptors with the same mechanism as an Ozempic injection of 0.5 mg. The molecule is not different.
The clinical oversight requirement is also the same. Both require a prescription from a licensed provider. Both require a physician to assess candidacy, manage titration, and monitor for contraindications and side effects. Neither is available without clinical involvement.
What Is Different
Manufacturer. Ozempic and Wegovy are manufactured by Novo Nordisk under FDA-approved conditions. Compounded semaglutide is produced by a licensed compounding pharmacy — ideally a 503B outsourcing facility under cGMP standards — rather than by the originator pharmaceutical company.
Delivery device. Ozempic and Wegovy come in prefilled, dose-dialing autoinjector pens — a user-friendly device that makes the injection process straightforward. Compounded semaglutide is typically dispensed in multi-dose vials with separate syringes. The mechanism is identical; the device is different. Most patients adapt to vial-and-syringe administration quickly with proper instruction.
Inactive ingredients. Brand-name semaglutide formulations contain specific stabilizers, buffers, and pH adjusters optimized by Novo Nordisk. Compounded versions use similar but not identical excipients. For most patients, this has no clinical significance. For patients with specific sensitivities to pharmaceutical excipients, it is worth discussing with your provider.
Price. This is the most practically significant difference for most patients. Brand-name Ozempic and Wegovy carry list prices of $900 to $1,350 per month. Compounded semaglutide, through a telehealth membership, is available at a dramatically lower cost — making it accessible to patients who would otherwise not be candidates for GLP-1 therapy from a practical standpoint.
"Compounded semaglutide is not a lesser version of Ozempic. It is the same molecule, made by a different manufacturer, in a different device, at a different price. The quality difference is in the sourcing — not in the pharmacology."
What Actually Determines Compounded Quality
The FDA does not approve or evaluate specific compounded formulations — it regulates the facility and processes that produce them. This is why the facility standard matters so much. A 503B-registered facility producing compounded semaglutide under cGMP conditions, with lot testing documentation and U.S.-sourced raw materials, is producing a product that meets rigorous quality standards — even though it lacks the Novo Nordisk brand.
A grey-market supplier producing semaglutide without any FDA-regulated oversight is not producing a compounded pharmaceutical — they are producing a chemical of unknown quality and purity in an unregulated environment. The brand name versus compounded distinction is not the relevant quality variable. The facility standard is.
503B compounded semaglutide.
Physician supervised. U.S. supply chain.
When Brand Name Is Worth Prioritizing
If your insurance covers Ozempic or Wegovy — particularly Ozempic for a diabetes indication — the autoinjector convenience and originator manufacturing backing may make brand name the right choice for your situation. If you are paying out of pocket, compounded semaglutide from a properly regulated 503B facility gives you the same clinical outcome at a fraction of the cost, with the requirement that you use a vial and syringe rather than an autoinjector pen. That tradeoff is worth understanding clearly before you decide.